Antibacterials macrolides

Several studies support the notion that the basic mechanism by which many drugs prolong the QT interval is related to blockade of potassium currents. For instance, several antihistamines, antibacterial macrolides, fluoroquinolones and antipsychotics were shown to inhibit the rapid component of the delayed rectifier K+ current (fKr) in electrophysiological studies and to block potassium channels encoded by hERG [37-42]. 

Use of a hERG blocker in a patient also taking CYP3A4 inhibitors (e.g. antibacterial macrolides, azole antifungals, HIV protease inhibitors) or CYP2D6 inhibitors (quinidine, halofantrine, fluoxetine, paroxetine, thioridazine, terbinafine) the hERG blocker, if mostly metabolized by these CYP isoforms, may accumulate because... 

These studies on modifications to erythromycin A have provided a great deal of important and interesting pharmacokinetic improvements, broadening an antibacterial spectrum and developing potency. For details, see Weisblum [183] and Bryskier et al. [207, 208]. Further work on structure-activity relationships in macrolide antibiotics with due consideration for their water solubility will provide a sufficient opportunity to improve antibacterial macrolides. 

The 16-membered antibacterial macrolide niddamycin is produced by Strep-tomyces djakartensis as a mixture of aliphatic esters of the 3 "-hydroxyl, the secondary alcohol on the neutral sugar mycarose. Niddamycin A1 has a butyryl ester, whereas niddamycin has the isovaleryl ester at this position. In addition. 

A high-throughput method that combines on-line extraction and determination by LC-MS/MS has been developed for the screening of 13 multi-class antibacterials (macrolides, fluoroquinolones, lincosamides, and trimethoprim) in different animal muscle tissues. After sample deproteinization with acetontirile, the extracts were directly loaded onto the SPE cartridge, packed with an Oasis HLB... 

Although they share structural features with the antibacterial macrolides and the antifungal macrocylic polyenes, the avermectins are not usually grouped with those compounds since they have neither antibacterial nor antifungal activities nor do they inhibit protein or chitin syntheses as do the other two groups. In the avermectins the macrocycle is a backbone for further substitution with a spiroketal (C-17 to C-28), a hexahydrobenzofuran unit (C-2 to C-8a), and... 

Looking back to the discovery of nalidixic acid almost 30 years ago, enormous efforts have been made and a huge number of analogs synthetized to improve overall properties. If one considers the relatively simple chemical structure of quinolones in comparison to other classes of antibacterials (macrolides, aminoglucosides, P-lactams), one can wonder if there is room for innovation or... 

Antibacterial Macrolides. This is a large family of products characterized by a lactone ring of 12—16 atoms bearing two or more st ar substituents. The best-known representative is erythromycin, produced by Saccharopolyspora erythraea. It... 

Polyenes. These antifimgal macrolides differ from antibacterial macrolides in the size of the lactone ring, ranging from 26 to 38 atoms, and with the presence of a series of conjugated double bonds. The only member systemically used is amphotericin B, produced by Streptomyces nodosus. Antifungal activity is due to interference with membrane sterols, resulting in permeability alteration (O Fig. 9.5). 

An alternative is to attempt to find means to support the resolution of inflammation or the maintenance of a non-inflamed or non-inflammation prone state. The antibacterial macrolides are a class of compounds that appear to exert such an effect. Clinical studies of chronic macrolide therapy suggest that a general effect of the class is to reduce apparent inflammation in a way that is not easily explained by antibacterial effects alone. Rather, it appears that the macrolides modify the responsiveness of myeloid derived immune cells, notably neutrophils and macrophages, with the effect of promoting a pro-resolution state that may be observed in the balance of anti-and pro-inflammatory cytokines that these cells produce." ... 

Figure 6.1 Structures of non-antibacterial macrolide CSY0073 and azithromycin.

Figure 6.2 (a) Structures of non-antibacterial macrolides based on descladinosyl... 

Figure 6.3 Non-antibacterial macrolides reported in ref. 10 with an IC50 against Streptococcus pyogenes of greater than 64 tg mL . These structures have a blocking group preventing the interaction of the ribosome with the desosamine OH and amine groups.

If NAMs are to be successful in the clinic, they will need to preserve the clinical anti-inflammatoty efficacy of the antibacterial macrolides while also improving on the already good safety of the class. What stands in their favour is that after nearly 50 years of clinical experience with macrolides, their pharmacology is very well understood and key aspects of safety can be easily addressed. However, there is still much to learn about the clinical use of macrolides and in particular, the potential to reduce doses. In the past. 

---